Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Young, Kristina H ^a,b   Baird, Jason R ^a   Savage, Talicia ^a   Cottam, Benjamin ^a   Friedman, David ^a   Bambina, Shelly ^a   Messenheimer, David J ^a   Fox, Bernard ^a   Newel, Pippa ^a,b   Bahjat, Keith S ^a   Gough, Michael J ^a   Crittenden, Marka R ^a,b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Oregon Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST TUMOR; CANCER CONTROL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; HYPOFRACTIONATED RADIOTHERAPY; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RADIATION EXPOSURE; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TIME TO TREATMENT; ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; COLORECTAL NEOPLASMS; DRUG SCREENING; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; TIME FACTOR; TUMOR CELL CULTURE;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DOSE FRACTIONATION; FEMALE; IMMUNOTHERAPY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; RECEPTORS, OX40; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975524433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157164     Document Type: Article

References (39)

1. Gough MJ, Crittenden MR. Immune system plays an important role in the success and failure of conventional cancer therapy. Immunotherapy. 2012; 4(2):125-8. Epub 2012/02/22. doi: 10.2217/imt.11.157 PMID: 22339452.
2. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of experimental medicine. 2006; 203(5):1259-71. Epub 2006/04/26. doi: 10.1084/jem.20052494 PMID: 16636135; PubMed Central PMCID: PMC3212727.
3. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. The Journal of experimental medicine. 2007; 204(1):49-55. Epub 2007/01/11. doi: 10.1084/jem.20062056 PMID: 17210731; PubMed Central PMCID: PMC2118433.
4. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009; 114(3):589-95. doi: 10.1182/blood-2009-02-206870 PMID: 19349616
5. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010; 33(8):798-809. Epub 2010/09/16. doi: 10.1097/CJI.0b013e3181ee7095 PMID: 20842057; PubMed Central PMCID: PMC3563298.
6. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(2 Pt 1):728-34. Epub 2005/02/11. 11/2/728 [pii]. PMID: 15701862.
7. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. The Journal of clinical investigation. 2014; 124(2):687-95. Epub 2014/01/03. doi: 10.1172/JCI67313 PMID: 24382348; PubMed Central PMCID: PMC3904601.
8. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Science translational medicine. 2012;4(137):137ra74. Epub 2012/06/08. doi: 10.1126/scitranslmed.3003649 PMID: 22674552.
9. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England journal of medicine. 2012; 366 (10):925-31. Epub 2012/03/09. doi: 10.1056/NEJMoa1112824 PMID: 22397654; PubMed Central PMCID: PMC3345206.
10. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, et al. A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. Translational Oncology. 2012; 5(6):404-7. doi: 10.1593/tlo.12280 PMID: 23323154
11. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(12):4101-9. Epub 2011/05/12. doi: 10.1158/1078-0432.CCR-11-0407 PMID: 21558401; PubMed Central PMCID: PMC3117971.
12. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013; 1(2):92-8. doi: 10.1158/2326-6066.CIR-13-0082 PMID: 24777500.
13. Young KH, Newell P, Cottam B, Friedman D, Savage T, Baird J, et al. TGFbeta inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunol Res. 2014. Epub 2014/07/23. doi: 10.1158/2326-6066.CIR-13-0207 PMID: 25047233.
14. Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 1980; 40(7):2142-6. Epub 1980/07/01. PMID: 6992981.
15. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and cellular biology. 1992; 12(3):954-61. Epub 1992/03/01. 1312220; PubMed Central PMCID: PMC369527. PMID: 1312220
16. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer discovery. 2011; 1(1):54-67. doi: 10.1158/2159-8274.cd-10-0028 PMID: 22039576
17. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. Journal of immunology. 2001; 167(12):6804-11. Epub 2001/12/12. PMID: 11739496.
18. Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer science. 2008; 99(2):361-7. Epub 2008/01/19. CAS664 [pii] doi: 10.1111/j.1349-7006.2007.00664.x PMID: 18201271.
19. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of experimental medicine. 2013; 210(9):1695-710. Epub 2013/07/31. doi: 10.1084/jem.20130579 PMID: 23897981; PubMed Central PMCID: PMC3754863.
20. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunol Res. 2013; 1(1):32-42. Epub 2014/04/30. doi: 10.1158/2326-6066.CIR-13-0013 PMID: 24777248.
21. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. The Journal of experimental medicine. 2013; 210(11):2435-66. Epub 2013/10/16. doi: 10.1084/jem.20130762 PMID: 24127486; PubMed Central PMCID: PMC3804934.
22. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1 Mediated Anti-Tumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2014. doi: 10.1158/2326-6066.CIR-14-0196 PMID: 25527358.
23. Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature. 2015; 517(7535):489-92. doi: 10.1038/nature13898 PMID: 25363767; PubMed Central PMCID: PMCPMC4304785.
24. Redmond WL, Linch SN, Kasiewicz MJ. Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity. Cancer Immunology Research. 2013; 2(2):142-53. doi: 10.1158/2326-6066.cir-13-0031-t PMID: 24778278
25. Crittenden MR, Savage T, Cottam B, Bahjat KS, Redmond WL, Bambina S, et al. The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PloS one. 2013; 8(7):e69527. Epub 2013/08/13. doi: 10.1371/journal.pone.0069527 PMID: 23936036; PubMed Central PMCID: PMC3723876.
26. Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. PloS one. 2012; 7(6):e39295. Epub 2012/07/05. doi: 10.1371/journal.pone.0039295 PMID: 22761754; PubMed Central PMCID: PMC3386283.
27. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. Journal of immunology. 2013; 190(11):5874-81. Epub 2013/05/01. doi: 10.4049/jimmunol.1202612 PMID: 23630355; PubMed Central PMCID: PMC3660450.
28. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(4):907-17. Epub 2010/11/26. doi: 10.1158/1078-0432.CCR-10-1762 PMID: 21106727.
29. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(17):5379-88. Epub 2009/08/27. doi: 10.1158/1078-0432.CCR-09-0265 PMID: 19706802; PubMed Central PMCID: PMC2746048.
30. Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(2):597-606. Epub 2009/01/17. 15/2/597 [pii] doi: 10.1158/1078-0432.CCR-08-1277 PMID: 19147765.
31. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS one. 2014; 9(7):e101764. doi: 10.1371/journal.pone.0101764 PMID: 25013914; PubMed Central PMCID: PMC4094423.
32. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015. doi: 10.1038/nature14292 PMID: 25754329.
33. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine. 2010; 363(8):711-23. doi: 10.1056/NEJMoa1003466 PMID: 20525992.
34. Videtic GM, Stephans KL, Woody NM, Reddy CA, Zhuang T, Magnelli A, et al. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer. International journal of radiation oncology, biology, physics. 2014; 90(1):203-8. Epub 2014/07/13. doi: 10.1016/j.ijrobp.2014.05.017 PMID: 25015198.
35. Thibault I, Al-Omair A, Masucci GL, Masson-Cote L, Lochray F, Korol R, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. Journal of neurosurgery Spine. 2014; 21(5):711-8. Epub 2014/08/30. doi: 10.3171/2014.7.spine13895 PMID: 25170656.
36. Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21(16):3727-39. Epub 2015/04/15. doi: 10.1158/1078-0432.ccr-14-2824 PMID: 25869387; PubMed Central PMCID: PMCPMC4537844.
37. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 2008; 68(13):5206-15. Epub 2008/07/03. doi: 10.1158/0008-5472.CAN-07-6484 PMID: 18593921.
38. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013; 73(24):7189-98. Epub 2013/11/02. doi: 10.1158/0008-5472.CAN-12-4174 PMID: 24177180; PubMed Central PMCID: PMC3922072.
39. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. International journal of radiation oncology, biology, physics. 2013. Epub 2013/03/07. doi: 10.1016/j.ijrobp.2012.12.025 PMID: 23462419.